Gbg Forschungs Gmbh
Clinical trials sponsored by Gbg Forschungs Gmbh, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Can a PI3K inhibitor boost presurgery breast cancer treatment? Results expected Jan 2027 (estimated)
- New drug aims to stop breast cancer recurrence in High-Risk patients Results expected Mar 2027 (estimated)
-
Can a PI3K inhibitor boost presurgery breast cancer treatment?
Disease control Recruiting nowResearchers are testing whether adding the drug inavolisib to hormone therapy and the antibody combination trastuzumab plus pertuzumab helps shrink HER2-positive, HR-positive breast tumors before surgery. The trial enrolls 170 patients with early-stage breast cancer that has a PI…
Phase 2 • Sponsor: GBG Forschungs GmbH • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New combo therapy aims to slow advanced breast cancer in BRCA patients
Disease control Recruiting nowThis study tests whether adding elacestrant to the standard drug olaparib can help people with a certain type of advanced breast cancer (HR-positive, HER2-negative) that has a BRCA gene mutation. About 176 participants will be randomly assigned to receive either the combination o…
Phase 2 • Sponsor: GBG Forschungs GmbH • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Breast cancer survivors tracked for decades in global registry
Knowledge-focused Recruiting nowThis international registry follows people who took part in GBG clinical trials for early breast cancer, collecting health information long after those trials end. Researchers track survival, late side effects, and issues related to pregnancy, fertility, and quality of life. The …
Sponsor: GBG Forschungs GmbH • Aim: Knowledge-focused
Last updated Sep 17, 2026 00:00 UTC